Cargando…
Neurodegeneration as the presenting symptom in 2 adults with xeroderma pigmentosum complementation group F
OBJECTIVE: To describe the features of 2 unrelated adults with xeroderma pigmentosum complementation group F (XP-F) ascertained in a neurology care setting. METHODS: We report the clinical, imaging, molecular, and nucleotide excision repair (NER) capacity of 2 middle-aged women with progressive neur...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994703/ https://www.ncbi.nlm.nih.gov/pubmed/29892709 http://dx.doi.org/10.1212/NXG.0000000000000240 |
_version_ | 1783330486490234880 |
---|---|
author | Shanbhag, Niraj M. Geschwind, Michael D. DiGiovanna, John J. Groden, Catherine Godfrey, Rena Yousefzadeh, Matthew J. Wade, Erin A. Niedernhofer, Laura J. Malicdan, May Christine V. Kraemer, Kenneth H. Gahl, William A. Toro, Camilo |
author_facet | Shanbhag, Niraj M. Geschwind, Michael D. DiGiovanna, John J. Groden, Catherine Godfrey, Rena Yousefzadeh, Matthew J. Wade, Erin A. Niedernhofer, Laura J. Malicdan, May Christine V. Kraemer, Kenneth H. Gahl, William A. Toro, Camilo |
author_sort | Shanbhag, Niraj M. |
collection | PubMed |
description | OBJECTIVE: To describe the features of 2 unrelated adults with xeroderma pigmentosum complementation group F (XP-F) ascertained in a neurology care setting. METHODS: We report the clinical, imaging, molecular, and nucleotide excision repair (NER) capacity of 2 middle-aged women with progressive neurodegeneration ultimately diagnosed with XP-F. RESULTS: Both patients presented with adult-onset progressive neurologic deterioration involving chorea, ataxia, hearing loss, cognitive deficits, profound brain atrophy, and a history of skin photosensitivity, skin freckling, and/or skin neoplasms. We identified compound heterozygous pathogenic mutations in ERCC4 and confirmed deficient NER capacity in skin fibroblasts from both patients. CONCLUSIONS: These cases illustrate the role of NER dysfunction in neurodegeneration and how adult-onset neurodegeneration could be the major symptom bringing XP-F patients to clinical attention. XP-F should be considered by neurologists in the differential diagnosis of patients with adult-onset progressive neurodegeneration accompanied by global brain atrophy and a history of heightened sun sensitivity, excessive freckling, and skin malignancies. |
format | Online Article Text |
id | pubmed-5994703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-59947032018-06-11 Neurodegeneration as the presenting symptom in 2 adults with xeroderma pigmentosum complementation group F Shanbhag, Niraj M. Geschwind, Michael D. DiGiovanna, John J. Groden, Catherine Godfrey, Rena Yousefzadeh, Matthew J. Wade, Erin A. Niedernhofer, Laura J. Malicdan, May Christine V. Kraemer, Kenneth H. Gahl, William A. Toro, Camilo Neurol Genet Article OBJECTIVE: To describe the features of 2 unrelated adults with xeroderma pigmentosum complementation group F (XP-F) ascertained in a neurology care setting. METHODS: We report the clinical, imaging, molecular, and nucleotide excision repair (NER) capacity of 2 middle-aged women with progressive neurodegeneration ultimately diagnosed with XP-F. RESULTS: Both patients presented with adult-onset progressive neurologic deterioration involving chorea, ataxia, hearing loss, cognitive deficits, profound brain atrophy, and a history of skin photosensitivity, skin freckling, and/or skin neoplasms. We identified compound heterozygous pathogenic mutations in ERCC4 and confirmed deficient NER capacity in skin fibroblasts from both patients. CONCLUSIONS: These cases illustrate the role of NER dysfunction in neurodegeneration and how adult-onset neurodegeneration could be the major symptom bringing XP-F patients to clinical attention. XP-F should be considered by neurologists in the differential diagnosis of patients with adult-onset progressive neurodegeneration accompanied by global brain atrophy and a history of heightened sun sensitivity, excessive freckling, and skin malignancies. Wolters Kluwer 2018-06-08 /pmc/articles/PMC5994703/ /pubmed/29892709 http://dx.doi.org/10.1212/NXG.0000000000000240 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Shanbhag, Niraj M. Geschwind, Michael D. DiGiovanna, John J. Groden, Catherine Godfrey, Rena Yousefzadeh, Matthew J. Wade, Erin A. Niedernhofer, Laura J. Malicdan, May Christine V. Kraemer, Kenneth H. Gahl, William A. Toro, Camilo Neurodegeneration as the presenting symptom in 2 adults with xeroderma pigmentosum complementation group F |
title | Neurodegeneration as the presenting symptom in 2 adults with xeroderma pigmentosum complementation group F |
title_full | Neurodegeneration as the presenting symptom in 2 adults with xeroderma pigmentosum complementation group F |
title_fullStr | Neurodegeneration as the presenting symptom in 2 adults with xeroderma pigmentosum complementation group F |
title_full_unstemmed | Neurodegeneration as the presenting symptom in 2 adults with xeroderma pigmentosum complementation group F |
title_short | Neurodegeneration as the presenting symptom in 2 adults with xeroderma pigmentosum complementation group F |
title_sort | neurodegeneration as the presenting symptom in 2 adults with xeroderma pigmentosum complementation group f |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994703/ https://www.ncbi.nlm.nih.gov/pubmed/29892709 http://dx.doi.org/10.1212/NXG.0000000000000240 |
work_keys_str_mv | AT shanbhagnirajm neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT geschwindmichaeld neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT digiovannajohnj neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT grodencatherine neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT godfreyrena neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT yousefzadehmatthewj neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT wadeerina neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT niedernhoferlauraj neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT malicdanmaychristinev neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT kraemerkennethh neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT gahlwilliama neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf AT torocamilo neurodegenerationasthepresentingsymptomin2adultswithxerodermapigmentosumcomplementationgroupf |